Phase II study of vinflunine in malignant pleural mesothelioma.

Journal article

PURPOSE: Malignant pleural mesothelioma (MPM) is a disease of increasing incidence for which treatment options are limited. This study reports the clinical efficacy data for vinflunine, a novel microtubule inhibitor, in MPM. PATIENTS AND METHODS: Patients with a histologically confirmed diagnosis of MPM were eligible for enrollment onto this multicenter phase II trial if they had not received prior chemotherapy or radiotherapy and had measurable lesions by Response Evaluation Criteria in Sol...

Expand abstract

Authors: Talbot, D; Margery, J; Dabouis, G; Dark, G; Taylor, H

• Publication status: Published
• Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
• Volume: 25
• Issue: 30
• Pages: 4751-4756
• Publication date: 2007-10-01
• DOI: 10.1200/jco.2007.12.5641
• EISSN: 1527-7755
• ISSN: 0732-183X
• Language: English
• Keywords: Mesothelioma; Female; Humans; Pleural Neoplasms; Survival Rate; Middle Aged; Male; International Agencies; Aged; Treatment Outcome; Vinblastine